JUPW vs. ICCC, QNCX, LEXX, UNCY, ACHL, RVPH, MODD, RPID, CYTH, and NUTX
Should you be buying Jupiter Wellness stock or one of its competitors? The main competitors of Jupiter Wellness include ImmuCell (ICCC), Quince Therapeutics (QNCX), Lexaria Bioscience (LEXX), Unicycive Therapeutics (UNCY), Achilles Therapeutics (ACHL), Reviva Pharmaceuticals (RVPH), Modular Medical (MODD), Rapid Micro Biosystems (RPID), Cyclo Therapeutics (CYTH), and Nutex Health (NUTX). These companies are all part of the "medical" sector.
ImmuCell (NASDAQ:ICCC) and Jupiter Wellness (NASDAQ:JUPW) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk.
ImmuCell has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Jupiter Wellness has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500.
In the previous week, ImmuCell and ImmuCell both had 2 articles in the media. Jupiter Wellness' average media sentiment score of 1.59 beat ImmuCell's score of 0.37 indicating that ImmuCell is being referred to more favorably in the media.
ImmuCell has higher revenue and earnings than Jupiter Wellness. ImmuCell is trading at a lower price-to-earnings ratio than Jupiter Wellness, indicating that it is currently the more affordable of the two stocks.
13.5% of ImmuCell shares are held by institutional investors. Comparatively, 15.6% of Jupiter Wellness shares are held by institutional investors. 6.6% of ImmuCell shares are held by company insiders. Comparatively, 32.9% of Jupiter Wellness shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
ImmuCell received 121 more outperform votes than Jupiter Wellness when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 0.00% of users gave Jupiter Wellness an outperform vote.
ImmuCell has a net margin of -18.31% compared to ImmuCell's net margin of -210.13%. Jupiter Wellness' return on equity of -15.21% beat ImmuCell's return on equity.
Summary
ImmuCell beats Jupiter Wellness on 10 of the 14 factors compared between the two stocks.
Get Jupiter Wellness News Delivered to You Automatically
Sign up to receive the latest news and ratings for JUPW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JUPW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jupiter Wellness Competitors List
Related Companies and Tools
